Detlev Mennerich is Senior Investment Manager at the Boehringer Ingelheim Venture Fund. Over the last five years, he led several investments of the therapeutics fund. He served as board member of ViraTherapeutics GmbH in Innsbruck (Austria), which was acquired by Boehringer Ingelheim in September 2018. Currently, Detlev serves at the Board of Imcheck Therapeutics in Marseilles (France), HepaRegenix in Tübingen (Germany), Topas Therapeutics in Hamburg (Germany), as well as of NBE Therapeutics in Basel (Switzerland). In addition, he is member of the Supervisory and the Scientific Advisory Board of Advent France Biotechnology, a French Seed Investment Fund based in Paris (France). Detlev Mennerich studied Chemistry in Braunschweig (Germany) and Bordeaux (France) and holds a PhD in Cell & Molecular Biology. In 2001, he started his industrial career at metaGen Pharmaceuticals and Schering AG in Berlin (Germany) as a Scientist in Oncogenomics focusing on target validation and biomarker research. In 2005, he joined Boehringer Ingelheim in Biberach an der Riss (Germany), where he held several positions in Research: he started as Laboratory Head in Genomics for new drug concept nominations. In 2009, Detlev moved to Ridgefield, CT (USA) as Project Leader for an anti-inflammatory antibody project. In 2011, he returned to Biberach heading the Target Validation Technologies Group supporting all diseases areas in new drug concept creation. Beginning of 2014, he joined the Boehringer Ingelheim Venture Fund investing in clinical translation of pioneering therapeutic approaches, i.e. in the field of immuno-oncology, immuno-tolerization and regenerative concepts.